lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-17. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Francium halides === Francium halides are all soluble in water and are expected to be white solids. They are expected to be produced by the reaction of the corresponding halogens. For example, francium chloride would be produced by the reaction of francium and chlorine. Francium chloride has been studied as a pathway to separate francium from other elements, by using the high vapour pressure of the compound, although francium fluoride would have a higher vapour pressure.
== Pharmaceutical variants == The recombinant human G-CSF (rhG-CSF) synthesised in an E. coli expression system is called filgrastim. The structure of filgrastim differs slightly from the structure of the natural glycoprotein. Most published studies have used filgrastim. The Food and Drugs Administration (FDA) first approved filgrastim on February 20, 1991, marketed by Amgen with the brand name Neupogen. It was initially approved to reduce the risk of infection in patients with non-myeloid malignancies who are taking myelosuppressive anti-cancer drugs associated with febrile neutropenia with fever. Several bio-generic versions are now also available in markets such as Europe and Australia. Filgrastim (Neupogen) and PEG-filgrastim (Neulasta), or pegylated form of filgratim, are two commercially available forms of rhG-CSF. The pegylated form of filgratim form has a much longer half-life, reducing the necessity of daily injections. The FDA approved the first biosimilar of Neulasta in June 2018. It is made by Mylan and sold as Fulphila. Another form of rhG-CSF called lenograstim is synthesised in Chinese hamster ovary cells (CHO cells). As this is a mammalian cell expression system, lenograstim is indistinguishable from the 174-amino acid natural human G-CSF. No clinical or therapeutic consequences of the differences between filgrastim and lenograstim have yet been identified, but there are no formal comparative studies.
3 January 1919: to avoid anarchy in Greater Poland, the Commission of the NRL decides to take over control of the spontaneous uprising but also decides that the decision should be kept secret. 4 January 1919: The Commission of the NRL decrees a new president of the Province of Poznań, Wojciech Trąmpczyński. German authorities call for boycotting him. 5 January 1919: Czarnków, Jutrosin, Kruszwica, Nakło, Nowy Tomyśl, Miejska Górka, Rawicz, Strzelno and Wolsztyn are captured by the Poles. 6 January 1919 The Poles capture Ławica Airport, Poznań, with all aircraft undamaged. Fighting near Czersk and Kościerzyna in Pomerania. Inowrocław captured. 7 January 1919 The Poles divide captured lands into seven Military Districts (Okręg Wojskowy). The Germans recapture Chodzież and Czarnków. 8 January 1919 The Commission of the NRL takes all civil and military authority without declaring territorial range of that power. It also promotes General Józef Dowbor-Muśnicki to commander-in-chief of the uprising forces. The Poles recapture Chodzież Battle of Chodzież and Czarnków. They also win the Battle of Ślesin and capture Sieraków. 9 January 1919 The NRL officially announces that it takes control over Greater Poland. Beginning of polonisation of administration, most former anti-Polish officials being fired. In powiats, German landrats are subordinated to Polish starostas, which take all their power. Poles lose Nakło. Polish airmen bomb military airfield in Frankfurt (Oder) 10 January 1919: fights on southern front near Kąkolewo, Leszno and Rydzyna. Poles capture Sarnowa.
==== Hepatitis ==== In this pattern, hepatocellular necrosis is associated with infiltration of inflammatory cells. There can be three types of drug-induced hepatitis. (A) viral hepatitis is the most common, where histological features are similar to acute viral hepatitis. (B) in focal or non-specific hepatitis, scattered foci of cell necrosis may accompany lymphocytic infiltration. (C) chronic hepatitis is very similar to autoimmune hepatitis clinically, serologically, and histologically.
Sources: en.wikipedia.org
== T == T cell - T-cell antigen receptors - tachykinin - tachykinin receptor - talin protein - tandem repeat sequence - taste bud - TATA box - tax gene product - taxonomy - telophase - tertiary structure - tetrodotoxin - thermochemistry - thermometer - thiamin - thioredoxin - threonine - thrombin - thrombin receptor - thrombomodulin - thromboxane receptor - thylakoid - thyroid hormone receptor - thyrotropin - thyrotropin receptor - thyrotropin-releasing hormone receptor - thyroxine - timeline of biology and organic chemistry - titration - tobacco mosaic virus - topoisomerase - toxin - trans-activator - transcription factor - transcription factor AP-1 - transducin - transformation - transforming growth factor - transforming growth factor alpha - transforming growth factor beta - transforming growth factor beta receptor - transient receptor potential - translation (biology) - transmembrane ATPase - transmembrane helix - transmembrane protein - transmembrane receptor - transport protein - transport vesicle - triiodothyronine - trinucleotide repeat - triose - tropomyosin - troponin - tryptophan - tubulin - tumor necrosis factors - tumor necrosis factor receptor - tyrosine - tyrosine 3-monooxygenase
==== Coffee ==== The world's primary source of caffeine is the coffee "bean" (the seed of the coffee plant), from which coffee is brewed. Caffeine content in coffee varies widely depending on the type of coffee bean and the method of preparation used; even beans within a given bush can show variations in concentration. In general, one serving of coffee ranges from 80 to 100 milligrams, for a single shot (30 milliliters) of arabica-variety espresso, to approximately 100–125 milligrams for a cup (120 milliliters) of drip coffee. Arabica coffee typically contains half the caffeine of the robusta variety. In general, dark-roast coffee has slightly less caffeine than lighter roasts because the roasting process reduces caffeine content of the bean by a small amount.
Venlafaxine was originally marketed as Effexor in most of the world; generic venlafaxine has been available since around 2008 and extended-release venlafaxine has been available since around 2010. Venlafaxine is sold under many brand names worldwide. In some countries, Effexor is marketed by Viatris after Upjohn was spun off from Pfizer.
Sources: en.wikipedia.org
Symptoms include daily abdominal and stomach pain, nausea, severe distension, vomiting, heartburn, dysphagia, diarrhea, constipation, dehydration and malnutrition. There is no cure for intestinal pseudo-obstruction. Different types of surgery and treatment managing life-threatening complications such as ileus and volvulus, intestinal stasis which lead to bacterial overgrowth, and resection of affected or dead parts of the gut may be needed. Many patients require parenteral nutrition. Ileus is a blockage of the intestines. Coeliac disease is a common form of malabsorption, affecting up to 1% of people of northern European descent. An autoimmune response is triggered in intestinal cells by digestion of gluten proteins. Ingestion of proteins found in wheat, barley and rye, causes villous atrophy in the small intestine. Lifelong dietary avoidance of these foodstuffs in a gluten-free diet is the only treatment. Enteroviruses are named by their transmission-route through the intestine (enteric meaning intestinal), but their symptoms are not mainly associated with the intestine. Endometriosis can affect the intestines, with similar symptoms to IBS. Bowel twist (or similarly, bowel strangulation) is a comparatively rare event (usually developing sometime after major bowel surgery). It is, however, hard to diagnose correctly, and if left uncorrected can lead to bowel infarction and death.
d-Synephrine also competitively inhibited the binding of nisoxetine to rat brain cortical slices, with a Ki = 4.5 μM; l-synephrine was less potent (Ki = 8.2 μM). In experiments on the release of [3H]-norepinephrine from rat brain cortical slices, however, the l-isomer of synephrine was a more potent enhancer of the release (EC50 = 8.2 μM) than the d-isomer (EC50 = 12.3 μM). This enhanced release by l-synephrine was blocked by nisoxetine. Burgen and Iversen, examining the effect of a broad range of phenethylamine-based drugs on [14C]-norepinephrine-uptake in the isolated rat heart, observed that racemic synephrine was a relatively weak inhibitor (IC50 = 0.12 μM) of the uptake. Another receptor-oriented study by Wikberg revealed that synephrine (stereochemistry unspecified) was a more potent agonist at guinea pig aorta α1 receptors (pD2 = 4.81) than at ileum α2 receptors (pD2 = 4.48), with a relative affinity ratio of α2/α1 = 0.10. Although clearly indicating a selectivity of synephrine for α1 receptors, its potency at this receptor sub-class is still relatively low, in comparison with that of phenylephrine (pD2 at α1 = 6.32). Brown and co-workers examined the effects of the individual enantiomers of synephrine on α1 receptors in rat aorta, and on α2 receptors in rabbit saphenous vein. In the aorta preparation, l-synephrine gave a pD2 = 5.38 (potency relative to norepinephrine = 1/1000), while d-synephrine had a pD2 = 3.50 (potency relative to norepinephrine = 1/50000); in comparison, l-phenylephrine had pD2 = 7.50 (potency relative to norepinephrine ≃ 1/6).
None of them ever denied the charges that they were Freemasons, and when asked, readily stated the positions that they held. However, even in captivity they were able to raise $1,632 to repair the chapel of the Catholic Church. The Parish Priest and the prison doctor then successfully petitioned the Spanish to release those Freemasons from prison.
=== Portugal === In Portugal, a resident physician is one undergoing postgraduate training aimed at obtaining a medical specialty. This training period begins after completing medical school and can last between 5 and 7 years, depending on the chosen specialty. At the end of their residency, physicians attain the status of specialist. The Medical Residency in Portugal is regulated by Decree-Law No. 60/2007, of March 13, and by Ordinance No. 183/2006, of February 22 (Medical Residency Regulation). It is organized into two training periods: the Common Year and the Professional Specialization Area. Until 2004, the residency was divided into General (2 years) and Complementary (3 to 6 years) phases. Upon completing medical school, doctors apply to a national competition for admission into the Medical Residency. This competition determines their placement for training locations and specialties, prioritizing the score obtained in a national ranking exam (a test with one hundred questions and five multiple-choice answers). The second criterion, used only in cases of a tie, is the medical school final grade. There is frequent confusion between a resident physician and an internal medicine specialist, also known as an internist. These terms are not synonymous, even though a resident physician may be pursuing specialization in internal medicine. The Portuguese Medical Association is the entity that regulates medical practice in Portugal, ensuring the technical-scientific postgraduate training of its members through residency programs, which grant physicians specialist status.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.